Jury Awards $27.8 Million in First Successful Xarelto Verdict
Posted on behalf of Goldberg Finnegan, LLC on Dec 28, 2017 in Drug Litigation
In early December, a Philadelphia jury ordered drug manufacturers Johnson & Johnson and Bayer AG to pay $27.8 million to an Indiana couple over bleeding injuries caused by Xarelto, a popular blood thinning drug. The jury found the manufacturers failed to properly warn patients of the internal bleeding risks linked to Xarelto.
This case was the first of four Xarelto cases that have gone to trial to recover a verdict. The award included $18 million in actual damages and $26 million in punitive damages.
If you have suffered an injury after being prescribed Xarelto or another anticoagulant drug, contact Goldberg Finnegan’s experienced drug injury attorneys for a free, no-obligation consultation. Our attorneys will review your case and inform you if filing a Xarelto lawsuit to recover compensation for your injuries is a possibility.
Dangerous Effects Associated with Xarelto
Xarelto was first approved for treating atrial fibrillation in 2011 by the U.S. Food and Drug Administration (FDA). It is also used to lower risks associated with deep vein thrombosis and pulmonary embolisms. The manufacturers promoted Xarelto as a superior option to popular anticoagulant Warfarin, which had been on the market for decades.
According to the FDA, Xarelto has been linked to at least 370 deaths, severe and fatal bleeding, thromboembolism, and blood clots. A common side effect of Xarelto is uncontrollable bleeding, for which there is no treatment. Due to the lack of cure for this common side effect, many victims allege Xarelto is dangerous and defective.
Xarelto has generated substantial revenue for both manufacturers, earning $3.42 billion for Bayer AG and $2.2 billion for Johnson & Johnson in 2016.
Victim Suffers Severe Internal Bleeding After Taking Xarelto
In this first successful Xarelto trial, the victim was prescribed Xarelto for the treatment of her atrial fibrillation and for stroke prevention. The 75-year-old woman took the medication for more than a year before being hospitalized in 2014 due to severe gastrointestinal bleeding.
The victim was switched to another blood thinner after undergoing four blood transfusions to replace blood loss stemming from her use of Xarelto. She reports no problems on the new anticoagulant.
The lawsuit claims manufacturers Bayer AG and Johnson & Johnson did not properly warm physicians and patients that Xarelto posed a risk of uncontrollable bleeding in certain patient groups. While the drug’s label warns that internal bleeding may occur, the lawsuit states the risk of bleeding out was not on the warning labeled. Former FDA Chief David Kessler corroborated this claim as he testified for the victim during trial.
In previous trials, Mississippi and Louisiana juries ruled that Xarelto’s labeling did properly warn of the drug’s bleeding risks.
More than 20,000 Xarelto lawsuits are pending throughout the country. Both Bayer AG and Johnson & Johnson have announced plans to appeal this most recent verdict.
Contact Our Dedicated Defective Drug Lawyers
If you suffered serious side effects after taking Xarelto, or lost a loved one due to complications with Xarelto, you may be able to join a Xarelto class action lawsuit to recover compensation for your medical bills, lost wages, and pain and suffering.
Our Silver Spring defective drug lawyers fight to hold negligent drug manufacturers accountable for the damages their defective medications cause. We will work to recover the compensation you deserve for your injuries.
Schedule a free, no-obligation consultation and learn what legal options may be available to you. Our attorneys work on a contingency fee basis, so legal fees are only paid if we are successful in recovering compensation for you.